Lifastuzumab Biosimilar Antibody-Drug Conjugate (SLC34A2) for Research
Pre-Made Lifastuzumab biosimilar, Whole mAb ADC, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lifastuzumab vedotin, also known as DNIB0600A and RG-7599, is a novel antibody-drug conjugate being developed by Genentech/Roche, in clinical trials. The investigational drug is being compared to pegylated liposomal doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-311-1mg | 1mg | 4635 |
| GMP-Bios-ab-311-10mg | 10mg | |
| GMP-Bios-ab-311-100mg | 100mg | |
| GMP-Bios-ab-311-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lifastuzumab biosimilar, Whole mAb ADC, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody |
| INN Name | Lifastuzumab |
| Target | SLC34A2 |
| Format | Whole mAb ADC |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer |
| Development Tech | na |
About target - SLC34A2
1. Protein Sodium-dependent phosphate transport protein 2B
2. Gene SLC34A2
3. Organism Homo sapiens (Human)
Function
May be involved in actively transporting phosphate into cells via Na+ cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.
pH dependence
Optimum pH is 6.6.

